BriaCell Therapeutics Corp. - Common Shares (BCTX)

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients, the company said.

Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

BriaCell Therapeutics shares are trading lower by 40% Thursday afternoon. The company announced the pricing of a $5.5 million public offering.

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

Let's have a look at the gap up and gap down stocks in today's session.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast cancer patients treated with Bria-IMT and an immune checkpoint inhibitor.

BCTX stock results show that BriaCell Therapeutics beat analyst estimates for earnings per share the third quarter of 2024.

Pre-market stock movers are a hot topic as investors return to trading on Tuesday following the long holiday weekend!

Pre-market stock movers are worth checking out as we have all of the hottest market news available on Tuesday morning!

BriaCell Therapeutics just reported results for the second quarter of 2024.

Our economy has and will continue to show strength and resilience, you should invest in these three penny stocks to buy quick.